Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3038570 | 0.91 | FGFR1 (0.39) | FGFR1ALDH1A1KDM4EMEN1NPC1 | |
| SCHEMBL6489898 | 0.89 | FGFR1 (0.42) | FGFR1ALDH1A1KDM4EMEN1NPC1 | |
| SCHEMBL3039306 | 0.87 | FGFR1 (0.45) | FGFR1ALDH1A1KDM4EMEN1NPC1 | |
| SCHEMBL3044076 | 0.82 | KDR (0.40) | FGFR1ALDH1A1KDM4EMEN1NPC1 | |
| SCHEMBL3050411 | 0.80 | FGFR1 (0.33) | FGFR1IP6K1 | |
| SCHEMBL3044219 | 0.80 | DRD1 (0.35) | FGFR1IP6K1 | |
| SCHEMBL3047005 | 0.80 | ALDH1A1 (0.35) | FGFR1ALDH1A1KDM4ENPC1HTT | |
| SCHEMBL3046969 | 0.80 | DRD1 (0.35) | FGFR1IP6K1 | |
| SCHEMBL3050820 | 0.79 | FGFR1 (0.42) | FGFR1ALDH1A1KDM4EMEN1NPC1 | |
| SCHEMBL3048638 | 0.79 | BRD4 (0.43) | FGFR1ALDH1A1KDM4EMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861530-B2 | Piperidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-03-01 | — | — | US | disclosed |
| US-6492392-B1 | INHIBITING TUMOR CELL PROLIFERATION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| US-20020137770-A1 | Piperidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-09-26 | — | — | US | disclosed |
| WO-2001085716-A1 | 2-PIPERIDONE COMPOUNDS FOR THE TREATMENT OF CANCER | KYOWA HAKKO KOGYO CO., LTD (JP) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137770-A1 | Piperidine derivatives | CIP2A, PARP2, TP53 | FGFR1 4100/4885ALDH1A1 270/4885KDM4E 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.